VERV - Verve Therapeutics, Inc.
IEX Last Trade
6.02
0.030 0.498%
Share volume: 47,446
Last Updated: Fri 27 Dec 2024 08:30:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.99
0.03
0.50%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-07 | 2023-03-02 | 2023-05-15 | 2023-08-10 | 2023-11-07 | 2024-02-27 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 324.267 M | 673.355 M | 679.223 M | 634.376 M | 589.131 M | 612.407 M | 752.688 M | 732.357 M | |
| Current Assets | 298.644 M | 561.630 M | 563.159 M | 517.787 M | 473.066 M | 498.261 M | 637.949 M | 620.326 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.083 M | 9.991 M | 7.339 M | 7.696 M | 8.497 M | 9.890 M | 8.102 M | 8.192 M | |
| Short Term Investments | 5.083 M | 9.991 M | 7.339 M | 7.696 M | 8.497 M | 9.890 M | 8.102 M | 8.192 M | |
| Total Receivables | 0.000 | 929.000 K | 1.012 M | 1.404 M | 2.093 M | 3.145 M | 5.897 M | 5.767 M | |
| Current Cash | 293.561 M | 550.710 M | 554.808 M | 508.687 M | 462.476 M | 485.226 M | 623.950 M | 606.367 M | |
| Total Non-current Assets | 25.623 M | 111.725 M | 116.064 M | 116.589 M | 116.065 M | 114.146 M | 114.739 M | 112.031 M | |
| Property Plant Equipment | 12.354 M | 15.159 M | 18.778 M | 21.053 M | 21.252 M | 20.803 M | 22.505 M | 21.024 M | |
| Other Assets | 8.032 M | 91.742 M | 92.462 M | 90.712 M | 89.989 M | 88.569 M | 87.460 M | 86.233 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 324.267 M | 673.355 M | 679.223 M | 634.376 M | 589.131 M | 612.407 M | 752.688 M | 732.357 M | |
| Total liabilities | 27.934 M | 125.412 M | 128.291 M | 124.900 M | 123.909 M | 152.038 M | 153.186 M | 149.288 M | |
| Total current liabilities | 25.847 M | 29.018 M | 35.095 M | 33.552 M | 33.031 M | 34.575 M | 37.006 M | 31.294 M | |
| Accounts Payable | 6.320 M | 465.000 K | 2.424 M | 3.372 M | 3.146 M | 1.054 M | 6.636 M | 3.049 M | |
| Other liabilities | 2.087 M | 25.383 M | 23.182 M | 22.421 M | 23.059 M | 50.774 M | 51.465 M | 54.540 M | |
| Current long term debt | 907.000 K | 8.904 M | 11.904 M | 11.184 M | 10.046 M | 10.118 M | 10.192 M | 10.220 M | |
| Long term debt | 0.000 | 71.011 M | 70.014 M | 68.927 M | 67.819 M | 66.689 M | 64.715 M | 63.454 M | |
| Other liabilities | 2.087 M | 25.383 M | 23.182 M | 22.421 M | 23.059 M | 50.774 M | 51.465 M | 54.540 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 296.333 M | 547.943 M | 550.932 M | 509.476 M | 465.222 M | 460.369 M | 599.502 M | 583.069 M | |
| Common stock | 48.675 M | 57.207 M | 61.641 M | 61.787 M | 61.954 M | 63.212 M | 69.747 M | 83.133 M | |
| Retained earnings | -257.962 M | -303.152 M | -344.237 M | -396.212 M | -450.195 M | -495.953 M | -544.305 M | -593.041 M |